{'fraction_non_alphanumeric': 0.017204301075268817, 'fraction_numerical': 0.013978494623655914, 'mean_word_length': 4.81875, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Transfer of spleen cells from young to aging NZB X NZW F1 hybrid mice. Effect on mortality, antinuclear antibody, and renal disease.

Multiple injections of spleen cells from young NZB x NZW F1 hybrid mice with a mean age of 9 weeks were administered to syngeneic recipients at 10-day intervals beginning at 3 months of age. The recipient mice had a dealyed appearance of antinuclear antibody, decreased cumulative incidence of antinuclear antibody positivity up to 7.3 months of age, lower cumulative mortality up to 8 months of age, and a lesser degree of glomerular sclerosis at 8 months of age. By 9 months of age no significant differences in these parameters remained. Transferred cells were most effective during the 4- to 6-week period immediately following initiation of injections. The beneficial effects appeared to reflect an early but temporary suppression of the autoimmune process by the transferred lymphoid cells.